Welcome to our dedicated page for Mereo Biopharma SEC filings (Ticker: MREO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Mereo Biopharma’s clinical milestones—whether a pivotal setrusumab result or a new Ultragenyx payment—means digging through dense disclosures that can span hundreds of pages. Financial professionals often need to find cash-runway data, partnership terms, or insider confidence indicators fast, yet Mereo Biopharma insider trading Form 4 transactions, R&D footnotes, and risk factors are scattered across multiple forms.
Stock Titan’s AI decodes every document the moment it lands on EDGAR. Need a Mereo Biopharma quarterly earnings report 10-Q filing? Our engine highlights trial spend and liquidity in seconds. Looking for Mereo Biopharma Form 4 insider transactions real-time? Instant alerts show you each trade. From 10-Ks to 8-Ks, you’ll see Mereo Biopharma SEC filings explained simply, complete with plain-English summaries, peer comparisons, and red-flag detection—perfect for understanding Mereo Biopharma SEC documents with AI instead of wading through technical language.
Use our platform to dive straight into the details that move the stock: Mereo Biopharma earnings report filing analysis pinpoints phase-3 funding needs; Mereo Biopharma executive stock transactions Form 4 surfaces buying or selling before catalyst dates; Mereo Biopharma annual report 10-K simplified outlines royalty structures; Mereo Biopharma proxy statement executive compensation breaks down incentive alignment; and Mereo Biopharma 8-K material events explained gives you context around surprise capital raises or trial outcomes. Real-time updates, AI-powered summaries, and full coverage of every form mean you spend less time searching and more time making informed decisions.
Frazier Life Sciences entities report passive holdings in Mereo BioPharma (MREO), detailing share counts, ADS equivalents and ownership percentages. The filing shows Frazier Life Sciences Public Fund, L.P. directly holds 32,430,690 Ordinary Shares, represented by 6,486,138 American Depositary Shares, equal to 4.1% of the issuer's 795,001,444 outstanding Ordinary Shares used for the percentage calculation. Additional Frazier entities hold 8,941,155 Ordinary Shares (1.1%, 1,788,231 ADS), 4,065,485 Ordinary Shares (0.5%, 813,097 ADS) and 1,763,230 Ordinary Shares (0.2%, 352,646 ADS). Voting and dispositive power over these holdings is reported as shared, with no sole voting or dispositive power asserted by the listed reporting persons. The statement corrects prior attributions by clarifying that committee members of certain general partners are not attributed beneficial ownership of the shares held by the funds. The filing also includes a certification that the securities were not acquired to influence control of the issuer and disclaims that the reporting persons are necessarily members of a group or beneficial owners beyond what is expressly stated.
Janus Henderson Group plc and an affiliated fund report significant passive holdings in Mereo BioPharma Group plc American Depositary Shares. Janus Henderson Group plc beneficially owns 17,688,592 ADS, equal to 11.1% of the class, with shared voting and shared dispositive power only and no sole voting or dispositive power. An affiliated vehicle, Janus Henderson Biotech Innovation Master Fund Ltd, reports 15,203,597 ADS (9.6% of the class), also held with shared voting and dispositive power only.
The filing is a Schedule 13G/A disclosure indicating the holdings are reported as held in the ordinary course of business; the reporting persons certify the securities were not acquired to influence control of the issuer. The filing identifies reporting classifications and a power of attorney authorizing signatories to file required ownership reports.
Mereo BioPharma Group plc reported several financing and collaboration items including a £0.265 convertible loan note held by Novartis that was convertible at holder discretion and bore 9% interest with a maturity date of February 10, 2025. The company issued two tranches of Novartis warrants (2,000,000 in 2023 plus a 2020 tranche) exercisable at £0.265 until February 2028; warrants were recognized as equity instruments. The company issued ordinary shares to AstraZeneca as part of an amended license agreement and received an aggregate upfront payment of $5.0 million, plus a $0.5 million milestone paid upon execution, and issued additional shares later. Outstanding warrants equal approximately 0.3% of issued share capital as of June 30, 2025 (0.4% as of December 31, 2024). The filing discloses milestone receipts of $50.0 million under Ultragenyx (setrusumab), $4.0 million under Feng Biosciences (navicixizumab), and $1.0 million under ReproNovo (leflutrozole), plus later milestone payments noted. The company lists a range of development, regulatory, manufacturing, commercialization and intellectual property costs and risks that could affect timing and cash needs.
FAQ
What is the current stock price of Mereo Biopharma (MREO)?
What is the market cap of Mereo Biopharma (MREO)?
